Trial Profile
A Four Part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine, or Concurrent BYL719 and Capecitabine, or Concurrent BKM120 and Capecitabine and Trastuzumab, or Concurrent BKM120 and Capecitabine and Lapatinib in Patients With Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Dactolisib (Primary) ; Capecitabine; Lapatinib; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- 21 Aug 2019 Status changed from active, no longer recruiting to completed.
- 17 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 17 Apr 2017 Status changed from recruiting to active, no longer recruiting.